Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice-Reference-Cited by-同舟云学术

Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice

Published:2015-05-29 Issue:12 Volume:16 Page:12213-12229
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Jia Chunming,Huan Yi,Liu Shuainan,Hou Shaocong,Sun Sujuan,Li Caina,Liu Quan,Jiang Qian,Wang Yue,Shen Zhufang

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/16/6/12213/pdf

Reference44 articles.

1. Non-alcoholic fatty liver disease

2. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD);Bellentani;Ann. Hepatol.,2009

3. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

4. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment

5. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of the Pro12Ala gene polymorphism with treatment response to thiazolidinediones in patients with type 2 diabetes: a meta-analysis;International Journal of Diabetes in Developing Countries;2022-05-31

2. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease;International Journal of Molecular Sciences;2022-01-19

3. Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice;PLOS ONE;2021-05-13

4. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease;Cells;2020-07-08

5. Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin;Current Pharmaceutical Design;2020-04-23